We listened to Cempra (NASDAQ: CEMP) management’s investor conference call after receiving the Complete Response Letter (CRL) from the FDA regarding regulatory application for Solithromycin’s approval for the treatment of adult community-acquired bacterial pneumonia (CABP). The management plans to meet with the FDA to discuss FDA’s request for a comparative safety trial to study....More>>>
9 Reasons Retirement May Go Extinct
Chambers CEO: Already Working With Trump to Kill DOL Fiduciary Rule
Why Jack Bogle Prefers Index Funds to Index ETFs
The Department of Labor’s Conflict of Interest Rule, if implemented in its current form, will force advisors to choose between employer-sponsored retirement plan business and traditional wealth management, according to....More>>>
Do we need to remind you how hard biotech stocks have been hit this year? If you read this blog, probably not, but we’ll do it anyway. The iShares Nasdaq Biotechnology ETF (IBB) has fallen 24%, while Gilead Sciences (GILD) has declined 8.7%, Biogen (BIIB) has fallen 17%, Celgene (CELG) has dropped 16%, and Regeneron Pharmaceuticals (REGN) has plunged 32%. Yet despite these drops–and....More>>>
In tonight’s Presidential debate, the moderator Chris Wallace stated:
Secretary Clinton, I want to pursue your [economic] plan, because in many ways it is similar to the Obama stimulus plan in 2009, which has led to the slowest GDP growth since 1949.
[Entire transcript here]
Oops. I don’t know where Mr. Wallace learned his economics. I think he’s got the causality....More>>>
Is Twitter Inc. (TWTR) doomed?
That would certainly seem to be the case, given its stock market performance over the last couple of years.
After reporting almost flat user growth for the last couple of quarters, the San Francisco-based company reported mixed earnings yesterday. It beat analyst expectations for revenue but fell short in user numbers and future guidance. (See also:....More>>>